| Joseph Nicholas Deluca, MD, PHD | |
|
378 Center Pointe Circle, Suite 1280, Altamonte Springs, FL 32701-3442 | |
| (407) 862-5959 | |
| (407) 774-5573 |
| Full Name | Joseph Nicholas Deluca |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 378 Center Pointe Circle, Altamonte Springs, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114930633 | NPI | - | NPPES |
| 046585200 | Medicaid | FL |
| Mailing Address | Practice Location Address |
|---|---|
| Joseph Nicholas Deluca, MD, PHD 378 Center Pointe Circle, Suite 1280, Altamonte Springs, FL 32701-3442 Ph: (407) 862-5959 | Joseph Nicholas Deluca, MD, PHD 378 Center Pointe Circle, Suite 1280, Altamonte Springs, FL 32701-3442 Ph: (407) 862-5959 |
News Archive
The U.S. Food and Drug Administration today cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, called OVA1, helps patients and health care professionals decide what type of surgery should be done and by whom.
With a newly discovered method of assembling organic molecules, a team of Princeton University chemists may have found a way to sidestep many of the expensive and hazardous barriers that stand in the way of drug development.
CollaborativeCARE Conference (C3), the first healthcare conference designed to foster regional coordinated care by educating specialists, primary care physicians and patients, today announced an alliance with HIMSS that will provide customized access to health information technology at the inaugural C3 event in Long Beach, Calif., scheduled for Nov. 15-20, 2011.
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia.
Alkermes, Inc. today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. Data from the studies, ALK33-003 and ALK33-004, showed that ALKS 33 was generally well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once daily dosing.
› Verified 5 days ago